These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32459822)
1. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study. Nabitaka VM; Nawaggi P; Campbell J; Conroy J; Harwell J; Magambo K; Middlecote C; Caldwell B; Katureebe C; Namuwenge N; Atugonza R; Musoke A; Musinguzi J PLoS One; 2020; 15(5):e0232419. PubMed ID: 32459822 [TBL] [Abstract][Full Text] [Related]
2. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria. Abudiore O; Amamilo I; Campbell J; Eigege W; Harwell J; Conroy J; Jiboye J; Lufadeju F; Amole C; Wiwa O; Anweh D; Agbaji OO; Akanmu AS PLoS One; 2023; 18(5):e0284767. PubMed ID: 37196012 [TBL] [Abstract][Full Text] [Related]
3. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study. Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121 [TBL] [Abstract][Full Text] [Related]
4. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801 [TBL] [Abstract][Full Text] [Related]
5. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda. Wagner Z; Wang Z; Stecher C; Karamagi Y; Odiit M; Haberer JE; Linnemayr S J Int AIDS Soc; 2024 Aug; 27(8):e26350. PubMed ID: 39155425 [TBL] [Abstract][Full Text] [Related]
6. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795 [TBL] [Abstract][Full Text] [Related]
7. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D; BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115 [TBL] [Abstract][Full Text] [Related]
8. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487 [TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients. Kumarasamy N; Prabhu S; Chandrasekaran E; Poongulali S; Pradeep A; Chitra D; Balakrishnan R; Benson CA Clin Infect Dis; 2019 Mar; 68(6):1048-1051. PubMed ID: 30192925 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695 [TBL] [Abstract][Full Text] [Related]
11. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Osterholzer DA; Goldman M Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281 [TBL] [Abstract][Full Text] [Related]
12. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942 [TBL] [Abstract][Full Text] [Related]
14. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863 [TBL] [Abstract][Full Text] [Related]
15. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021. Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. Meireles MV; Pascom ARP; Duarte EC; McFarland W AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860 [TBL] [Abstract][Full Text] [Related]
17. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291 [TBL] [Abstract][Full Text] [Related]
18. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study. Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050 [TBL] [Abstract][Full Text] [Related]
19. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review. Rutherford GW; Horvath H PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]